27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
Agios Pharmaceuticals Inc (NASDAQ:AGIO), a pharmaceutical company that focuses on the field cellular metabolism to treat cancer and rare genetic diseases, is a stock investors should "own for the next several years," according to Piper Jaffray.
The Analyst
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!
Piper Jaffray's Tyler M. Van Buren initiated coverage of Agios Pharmaceuticals with an Overweight rating and $125 price target.
The Thesis
The bullish case for owning Agios' stock is four-fold, Van Buren said in a note.
- Agios and its partner Celgene (NASDAQ:CELG) received approval for its idhifa therapy and so far the launch has "gone well" and represents $200 million in potential U.S. sales. The company's tibsovo therapy is similar to idhifa and is under review but should be approved by the end of 2018 and generate another $100 to $150 million in potential sales.
- Idhifa and tibsovo have shown "encouraging data" in frontline AML, but Van Buren said the opportunities for the therapies will likely expand. Tibsovo, for example, is in a Phase 1 development cholangiocarcinoma and low-grade glioma.
- Phase 2 data for the company's AG-348 for the treatment pf Pyruvate Kinase Deficiency is favorable so far and indicates a durable 3.4 g/dL increase of hemoglobin in 50 percent of PKD patients.
- Agios faces a "very large" potential opportunity with its AG-270 for MTAP-deleted tumors. The company is expected to show initial data by early 2019 the latest and could ultimately serve more than 100,000 patients with MTAP-deleted tumors.
Price Action
Shares of Agios Pharmaceuticals closed higher by 3.58 percent at $93.50.
HC Wainwright: G1 Therapeutics Is Targeting 'Potential Blockbuster' Oncology Markets
Incyte Falls 20% After Cancer Drug Fails Phase 3 Trial
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.